We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test Identifies Pregnant Women at Risk for Preeclampsia

By Labmedica staff writers
Posted on 26 Mar 2008
A test that identifies pregnant women at risk of developing preeclampsia is performed from as early as the seventh week of pregnancy, and it predicts the appearance of the condition six months later. More...
The test results provide the physician with a useful tool to evaluate the surveillance and management of the pregnant woman.

According to the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), preeclampsia affects 5-7% of all pregnant women and represents a serious challenge for obstetricians, and prenatal and diagnostic laboratories. This disorder can result in loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver, and cardiovascular malfunctioning. It is a rapidly progressive condition characterized by sudden hypertension and an elevated protein level in urine.

Scientists from Diagnostic Technologies (Yokne'am Illit, Israel) developed a breakthrough technology that could help doctors identify pregnant women at risk of developing preeclampsia. The early detection is performed about 20 weeks before symptoms develop, and is based on the use of a simple blood test, which determines the level of a protein produced by the placenta--placenta protein 13 (PP13).

"Preeclampsia is the second most frequent cause of maternal death in pregnancy, but to our disappointment the dimension of the problem is not known to the public. Many women, pregnant or not, are unaware of the real risk,” said developmental neurobiologist Dr. Hamutal Meiri, CEO of Diagnostic Technologies. Early detection gives rise to prevention and management of the risk due to better pregnancy management and preventive treatment.”

The company is now working towards completing a study of the test with the aim of achieving U.S. Food and Drug Administration (FDA; Rockville, MD, USA) approval. Dr. Meiri said that they plan to complete development of a product dedicated to tailor medication to women at high risk for preeclampsia, and to identify families with a genetic disorder that predisposes to preeclampsia.


Related Links:
U.S. Centers for Disease Control and Prevention
Diagnostic Technologies
U.S. Food and Drug Administration

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.